NEW BLOG: In June, over $15 billion was raised by companies in the #biotech and #biopharma space. Katie Davis explores key findings within this blog and identifies the companies raising these funds. Read the blog here: https://lnkd.in/eRgkC-Tn
Invenia Group
Staffing and Recruiting
Global Talent & Executive Search Specialists to the Pharma, Scientific Process & Technology, and Medical Device markets
About us
We are Invenia, a global search and talent firm specialising in the pharmaceutical, scientific and process technology and medical device and technology sectors. Established in 2009, with a commitment to support our clients to build successful businesses, we have grown into a leading supplier across major global markets. We work with trail-blazing start-ups, SMEs and global leaders sourcing the very best in commercial, technical, strategic and executive talent. Our business is structured to deliver the best talent in the market. Our multi-lingual teams are focused on specific regions and markets enabling us to fully map out the talent landscape and engage with and attract all candidates regardless of language or location. Combined with our industry expertise, we source only the most qualified and talented individuals for your business reducing your time to hire and making the process as smooth as possible. Our aim is simple, to ensure our clients have the talent they need to succeed and our candidates secure jobs they love.
- Website
-
http://www.inveniagroup.com
External link for Invenia Group
- Industry
- Staffing and Recruiting
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Scientific recruitment, Healthcare recruitment, Life Sciences recruitment, Diagnostics recruitment, Pharma recruitment, Medical Technology recruitment, Biotech recruitment, Dental recruitment , and Medical Device recruitment
Locations
-
Primary
5th Floor, Runway East 18 Crucifix Lane
London, SE1 3JW, GB
-
Floor 2, Concordia works
30 Sovereign Street
Leeds, England LS1 4BA, GB
-
347 5th Ave
New York, NY 10016, US
Employees at Invenia Group
-
Chris Pickles
I build executive board teams in dynamic and emerging markets, along with recruiting top-tier C-suite executives specializing in Industrial…
-
Annee Sian
Head of Marketing at Invenia Group & CrimsonXT | Marketing Mentor | Scouting Volunteer
-
Christine Sands
I help pharmaceutical companies connect with senior professionals across Europe and the US.
-
Andrew Maddison
Director @ Invenia Group - Global Life Science, Diagnostics & Chemistry - Talent and Executive Search Specialist
Updates
-
Anteris Technologies has launched a $40 million equity raise to fund the development of its flagship DurAVR THV product, which aims to mimic a healthy aortic valve. Read the full article here: https://lnkd.in/eE6983Xc
-
Global Director Tanya Ridding received a fantastic #recommendation from a client she partnered with. Tanya has been praised for her #medicaldevice industry expertise, and abilities to identify talented individuals relevant for a variety of #opportunities. Congratulations, Tanya!
-
#Celltherapy first reached patients as treatments for cancer. Artiva Biotherapeutics is part of a growing group of companies working to bring cell therapy to #autoimmune #disease, and its IPO has raised $167 million for clinical trial plans. Artiva priced the IPO at $12 per share, which was below the $14 to $16 per share price range the #biotech set in preliminary terms last week. However, it boosted the deal size by increasing the number of shares in the offering. The 8.7 million shares it initially planned to offer would have raised $130.5 million at the proposed pricing midpoint. The company was able to raise more by selling 13.92 million shares. Read the full article here: https://lnkd.in/gdKyPjAb
Artiva’s IPO Reels In $167M to Bring NK Cell Therapy to Autoimmune Diseases - MedCity News
https://medcitynews.com
-
New life science vacancies this week! We have partnered with an incredible range of fast-growing and leading life science & pharmaceutical companies across the US. To find out more information, head over to our jobs page here: https://rb.gy/19iaq7 Director Global Logistics - Maryland, US: https://rb.gy/9lfh2t Senior Patent Agent - San Jose, US: https://rb.gy/jv7ccd Marketing Communications Manager - San Jose, US: https://rb.gy/o06qku Director (Scientific Affairs) - California, US: https://rb.gy/44thif Director (Scientific Affairs) - West Coast, US: https://rb.gy/uwalbp Haven't seen anything that's right for you? Why not register with us instead so we can find you your perfect role: https://lnkd.in/dpZiviy Ready to talk to a specialist recruiter to discuss a vacancy or set of vacancies? Maybe you’d like to learn more about our recruitment services? Get in touch here: https://lnkd.in/e9D6pugm #inveniajobs #pharma #pharmaceutical #lifescience #lifesciences #scientist #biotech #biopharma #diagnostics
-
NEW BLOG: The new UK #Labour government’s impact on the #Medtech sector will be multifaceted, involving changes across several key areas. This could present both opportunities and challenges for companies operating in this space depending on how they can adapt to the changes. In this blog, Tanya Ridding takes a look through some of the potential impacts we can foresee. Read the blog here: https://lnkd.in/eKbeJHgd
-
Swiss biotech company Asceneuron SA has raised $100 million from investors in a Series C funding round. The round was led by Novo Holdings, the investment arm of the Novo Nordisk Foundation, which will hold a board seat on the Lausanne-based company. Asceneuron will use the funds for a phase 2 trial that will begin later this year. Read the article here: https://lnkd.in/eXtFH8fb
Novo owner backs Swiss biotech Asceneuron in $100 million round
reuters.com
-
Invenia Group reposted this
Global Scientific Headhunter - Specialising in Emerging Technology e.g. Single Cell, Spatial Biology, Organoids etc.
🧬𝐂𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐭𝐢𝐚𝐥 𝐂 𝐒𝐮𝐢𝐭𝐞 𝐉𝐨𝐛 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲🧬 We have exclusively partnered with a growing company to fill an Executive Level Business Development role. We are looking for senior candidates in the #UK with extensive experience closing deals in the #bioinformatics space. If this is you please reach out for more detail!
-
Cardurion Pharmaceuticals is looking to challenge the statin-dominated cardiovascular status quo with a $260 million series B fundraising round. Cardurion plans to harness the fresh funds to support later-stage clinical trials of its two leading drug candidates, a phosphodiesterase-9 (PDE9) inhibitor called CRD-750 and a calcium–calmodulin-dependent protein kinase II (CaMKII) inhibitor called CRD-4730, both of which are currently in phase 2 clinical trials. Read the article here: https://lnkd.in/e5f56aWZ
Cardio-focused Cardurion closes hearty $260M series B to challenge statin-dominated status quo
fiercebiotech.com
-
Invenia Group reposted this
Global Scientific Headhunter - Specialising in Emerging Technology e.g. Single Cell, Spatial Biology, Organoids etc.
𝐈𝐧 𝐉𝐮𝐧𝐞, 𝐨𝐯𝐞𝐫 $𝟏𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐰𝐚𝐬 𝐫𝐚𝐢𝐬𝐞𝐝 𝐛𝐲 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐒𝐩𝐚𝐜𝐞. I have put together a summary of the money raised below 👇🏻👇🏻 𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀: 💰The largest amount of money raised was by Novartis who raised $2.49 billion in Post-IPO Debt 💰The largest amount raised by a private company was by Curie.Bio with a massive $380 million raised in its Series A funding round. 💰$2.94 billion was raised between Pre-Seed and Series E funding rounds. Companies in the article include: Cypris Therapeutics, Inc., Citizen Labs, ŌGI Bio, Ability Biologics, TwoStep Therapeutics, EpilepsyGTx, Waypoint Bio, EvolutionaryScale, Alida Biosciences, Moleculent, Amber Therapeutics, GPN Vaccines, Envisagenics, Interius BioTherapeutics, Enveda Biosciences, Santa Ana Bio, Inc., Frontier Medicines, BillionToOne, Formation Bio, Metabolon, Inc., Calico Biosystems, Fuse Diagnostics, Prompt Diagnostics, Nuclera, Mustang Bio, TME Pharma, ANGLE, Annexon Biosciences, Avidity Biosciences, Inc., Grifols, Novartis and many more!
Money Raised in June 2024
Katie Davis on LinkedIn